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A B S T R A C T
Although some risk factors for breast cancer might be protective for osteoporosis, several cross-sectional studies
have reported, nevertheless, that patients with breast cancer have a lower bone mass and potentially a higher
incidence of fractures than expected. In any case, it appears that patients with breast cancer are not protected
from osteoporosis, which provides further support for the recommendation that bone health is assessed after a
diagnosis of breast cancer. Most adjuvant therapies will lead to increased bone loss and a higher fracture rate.
Among the adjuvant therapy options for premenopausal patients with breast cancer, endocrine therapy (ovarian
suppression) and chemotherapy can result in cancer treatment-induced bone loss (CTIBL) of up to 10% at the
lumbar spine after one year. Antiresorptive therapies prevent CTIBL in premenopausal women with breast
cancer. Most of the evidence demonstrating the eﬃcacy of bisphosphonates in the prevention of CTIBL is derived
from clinical trials with zoledronic acid. The addition of zoledronic acid 4 mg per six months to adjuvant en-
docrine therapy maintained and even increased bone mass during a 3-year treatment period and signiﬁcantly
improved disease-free survival in a population of young women who underwent menopause due to the adjuvant
treatment. The major contributor to bone loss in the adjuvant treatment of breast cancer in postmenopausal
women is the use of aromatase inhibitors (AIs). Oncology trials have underestimated the fracture risk in the
setting of AI-induced bone loss. In the ABCSG-18 study, the only trial in which fracture incidence was the
primary endpoint, the rate of clinical fractures was close to 10% after 3 years in the placebo group on AIs only.
Bisphosphonates and denosumab at osteoporosis treatment doses can counteract AI-induced bone loss. In the
ABCSG-18 trial, treatment with denosumab 60 mg injection every 6 months reduced the risk of ﬁrst clinical
fracture relative to placebo by 50%. Current guidelines recommend antiresorptive therapy in patients with a
baseline T score of<−2.0 or with two or more clinical risk factors for fracture. These recent guidelines will
need to be updated, as similar signiﬁcant protective eﬀects were seen in women with either normal or low bone
mass. Moreover, a formal meta-analysis of individual patient data from more than 18,000 women in 26 ran-
domized trials of adjuvant zoledronic acid or clodronate treatment for early breast cancer revealed that bi-
sphosphonates signiﬁcantly reduced the risk of ﬁrst distant recurrence in bone and the risk of breast cancer
mortality, at least in postmenopausal women. Even though the increased risk of fracture during adjuvant
treatment for breast cancer in postmenopausal women is notable, an enhanced risk of fracture in long-term
survivors of breast cancer remains under debate. The most recent studies suggest that Caucasian breast cancer
survivors do not have a signiﬁcantly increased risk of osteoporotic fracture over the long term.
1. Introduction
Breast cancer is among the most common types of cancer in women.
Compared to older endocrine therapies, an increase in the survival of
patients with hormone receptor positive breast cancer has been ob-
served with the introduction of adjuvant therapy such as tamoxifen and
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aromatase inhibitors (AIs) [1–3]. A recent meta-analysis has shown that
the risk ratios for recurrence favoured AIs during periods when the
treatments diﬀered (Relative Risk [RR] 0.70, 0.64–0.77), and all-cause
mortality was also reduced with AIs (RR 0.88, 0.82–0.94; p = 0.0003)
[4].
Less than 10% of women are diagnosed with metastatic disease at
presentation; hence, the majority of breast cancer patients are treated
with an intention to cure. With more women surviving breast cancer
longer, maintaining their quality of life and avoiding treatment com-
plications are of primary importance. However, because the bone is also
an endocrine organ, these anti-hormonal therapies can have a negative
impact on bone health. Indeed, both AIs and tamoxifen inhibit the
stimulating eﬀect of oestrogen on breast tissue [5,6]. Consequently,
monitoring the long-term eﬀects of anti-hormonal therapies, including
bone health, is important.
The objective of this narrative review is to discuss the relation be-
tween breast cancer and bone health with a special focus on four issues
of potential relevance to the clinician: the fracture rate in breast cancer
patients before therapy, increased bone loss and fracture rate during
adjuvant therapy of breast cancer in premenopausal women and in
postmenopausal women and the fracture rate in long-term breast cancer
survivors.
2. Methods
The Belgian Bone Club board invited 8 experts in musculoskeletal
diseases and/or cancer (endocrinologists, rheumatologist, geriatrician,
clinical epidemiologists and scientists) to be part of a working group
discussing skeletal health in cancer survivors. Two of the participants
were entrusted with the task of preparing a literature review. A lit-
erature search was conducted in May 2017 using the MEDLINE/
PubMed database. The search strategy included a combination of the
following terms: cancer, recovery, survival, bone, osteoporosis, osteo-
penia and fracture. Additional references were selected from the re-
ference lists of the retrieved articles to broaden the literature search.
Only articles published in English were considered. This literature
search yielded more than 500 hits of which only a substantial subset
was retrieved according to their relevance to the topic. Our literature
review focused on the most robust available evidence when possible,
such as meta-analyses and prospective studies, with the most recent
publications consulted.
3. Results and discussion
3.1. Is the fracture rate decreased or increased in breast cancer patients
before therapy?
Some surrogate markers of the lifetime exposure to oestrogen could
be considered to play diﬀerent roles in fractures or breast cancer [7,8].
Indeed, late menarche, early menopause and a low body mass index,
are associated with an increased risk of osteoporotic fractures, whereas
early menarche, late menopause, postmenopausal use of Hormonal
Replacement Therapy (HRT) and high body mass index are known to be
risk factors for breast cancer. Thus, identifying the risk factors that
increase the incidence of breast cancer should theoretically help protect
against fracture occurrence. Moreover, a meta-analysis without speciﬁc
populations restriction, reported that a higher bone mineral density was
associated with a signiﬁcantly higher risk of breast cancer in post-
menopausal women [9]. The meta-analysis suggested that individuals
in the highest category of hip or spine BMD had a 62 or 82% higher risk
of breast cancer compared with those in the lowest category. Consistent
with this observation, prospective studies have suggested that patients
with bone fractures were at lower risk of breast cancer [10,11].
No prospective studies are available to assess the relation between
the incidence of fractures and breast cancer before therapy since most
of the patients are treated after its diagnosis. Since most of the current
− and past − treatments used in the management of breast cancer
could have an impact on bone health, they could be considered as
potential confounding factors when assessing the long-term relation
between breast cancer and bone heath.
Moreover, very few cross-sectional studies are available assessing
the prevalence of fractures in breast cancer patients before the initia-
tion of speciﬁc therapies. In a Spanish study of 343 women with early
breast cancer, aged 62 years on average, who were about to start ad-
juvant AI therapy, 17.7% had normal BMD, 60.1% had osteopenia,
22.2% had osteoporosis and 11.4% had a prevalent fracture [12]. In
another French study of 497 women with a mean age of 64 years who
were enrolled before starting AIs, 31.4% had a low bone mass (T-
score< 2 SD), 19.7% had vertebral fractures and 19.1% had a history
of non-vertebral fractures [13]. These percentages are higher than ex-
pected in a population of the same age and ethnicity without cancer,
but caution must be taken when interpreting these results because both
of these studies suﬀer from the lack of a control group without breast
cancer.
In the various AI trials, even if the prevalence of fractures at base-
line was not reported, a very low proportion of women with osteopenia
or osteoporosis was noted [14–16]. This ﬁnding suggests that patients
included in the large clinical trials might diﬀer from those seen in ac-
tual practice. That could have some implications when generalizing the
results of fracture incidence in these large clinical trials. Despite the
limited amount of data, these results suggest that bone health status
should be assessed after a diagnosis of breast cancer.
3.2. Increased bone loss during adjuvant therapy of breast cancer in
premenopausal women
Bone loss results from age, lifestyle, disease and treatment-related
inﬂuences on the normal bone turnover, more so at sites of the skeleton
characterized by a higher proportion of trabecular bone (e.g., the spine
and the proximal and distal ends of long bones). Bone loss leads to
thinning and perforation of the trabecular plates, and the subsequent
loss of normal architecture results in a disproportionate loss of strength
for the amount of bone lost, especially when the bone loss is markedly
accelerated. Oestrogen deﬁciency is the major cause of accelerated
bone loss leading to an increased incidence of fractures. In the setting of
adjuvant treatment for breast cancer, current treatment guidelines re-
commend that premenopausal women with hormone receptor-negative
disease receive adjuvant chemotherapy, and those with hormone re-
ceptor-positive disease receive adjuvant endocrine therapy (tamox-
ifen ± ovarian function suppression) with or without adjuvant che-
motherapy [17].
Among these adjuvant therapy options for premenopausal patients
with breast cancer, both endocrine therapy (tamoxifen whether com-
bined or not with ovarian suppression using GnRH agonists) and che-
motherapy can result in substantial bone loss from the suppression of
oestrogen levels, premature menopause, or direct negative eﬀects of
chemotherapy on bone [18–20]. Amenorrhea can therefore result from
ovarian function suppression or chemotherapy-induced ovarian failure.
Chemotherapy-induced ovarian dysfunction accelerates the onset of
menopause by an average of 10 years [21]. Between 25% and 100% of
premenopausal women may experience early menopause or amenor-
rhea, especially in women over 40 years of age [22]. Chemotherapy-
induced ovarian failure results in substantial bone mineral density
(BMD) loss of up to 6–8% at the lumbar spine after 1 year [23,24].
Ovarian function suppression with luteinizing hormone-releasing hor-
mone (LHRH) agonists such as goserelin leads to a mean 10.5% loss of
BMD at the lumbar spine and 6.4% at the femoral neck [25]. Tamoxifen
alone and in combination with a LHRH agonist are standards of care for
women with oestrogen receptor-positive breast cancer. Although ta-
moxifen is a selective oestrogen receptor modulator with some bone
protective activity in postmenopausal women, it has also been asso-
ciated with bone loss in premenopausal patients [18]. Changes in BMD
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or biochemical markers of bone resorption are surrogate markers for
fracture risk due to cancer treatment-induced bone loss (CTIBL), but no
fracture data are available in this particular adjuvant setting.
Antiresorptive therapies can eﬀectively prevent CTIBL in pre-
menopausal women with breast cancer. Most of the evidence for the
eﬃcacy of bisphosphonates in the prevention of CTIBL is derived from
clinical trials of zoledronic acid [23]. Zoledronic acid 4 mg, probably
preferably every 3 months as opposed to every 6 months over 1 year,
can completely prevent bone loss due to chemotherapy-induced ovarian
failure with a sustained beneﬁt 1 year after completion of therapy [26].
On the other hand, the Austrian Breast and Colorectal Cancer Study
Group 12 (ABCSG-12) trial has been the main preventive study of CTIBL
induced by hormonal therapy in premenopausal women [27]. More
than 1800 premenopausal women with early-stage breast cancer re-
ceived primary adjuvant endocrine therapy (ovarian suppression plus
tamoxifen or anastrazole) with or without zoledronic acid (4 mg every
6 months) for 3 years. The addition of zoledronic acid to adjuvant en-
docrine therapy maintained and even increased BMD during the 3-year
treatment period compared with a signiﬁcant BMD loss in the patients
who did not receive zoledronic acid (−11.3% at the lumbar spine;
−7.3% at the trochanter; P < 0.0001 for both) [27]. The beneﬁt was
sustained for at least 2 years after the end of the trial. Moreover, adding
zoledronic acid to adjuvant endocrine therapy signiﬁcantly improved
disease-free survival, and there was a trend for improved overall sur-
vival. Subgroup analyses conﬁrmed anticancer beneﬁts only in women
older than 40 years [27]. The tolerance of zoledronic acid at these
therapeutic schedules is excellent [28]. The selection of patients for
such prevention treatment remains, however, unclear.
Current fracture risk assessment tools are based on data from
healthy postmenopausal women and do not adequately address the
risks associated with treatments in younger premenopausal women.
Moreover, the International Society for Clinical Densitometry re-
commends using Z-scores in premenopausal women, which represent
the standard deviation of BMD relative to the expected BMD range for
women of similar age. Guidance from expert groups for premenopausal
women with breast cancer recommends that all premenopausal women
be informed about the potential risk of bone loss before beginning
anticancer therapy, with the use of antiresorptive therapy if the BMD Z-
score is<−2 or if the score is≤−1.0 with an annual decrease of BMD
of 5% to 10% [23]. We believe, however, that the clinicians should not
wait until such degree of bone damage occurs, and we believe that
antiresorptive therapy with zoledronic acid should be considered in all
premenopausal women with a low bone mass, i.e., a Z-score less than
−1, when starting hormone ablative therapy in premenopausal patients
with breast cancer.
3.3. Increased bone loss and increased fracture rate during adjuvant
therapy of breast cancer in postmenopausal women
The major contributor to bone loss in the adjuvant treatment of
breast cancer in postmenopausal women is the use of aromatase in-
hibitors. AIs improve the disease outcomes compared to tamoxifen and
have become the ﬁrst-line hormonotherapy in the adjuvant setting of
breast cancer, but bone loss is their main side eﬀect. AI therapy is as-
sociated with an average 2% loss of BMD at the lumbar spine per year,
and the eﬀects of AIs on cortical bone and bone strength appear to be
largely underestimated by classic dual-energy X-ray absorptiometry
(DXA) [29]. The FRAX model does not include anti-cancer treatments as
a speciﬁc risk factor and underestimates the fracture risk in the setting
of AI-induced bone loss. These agents prevent the conversion of an-
drogens to oestrogen by the aromatase enzyme, thereby rapidly and
dramatically reducing circulating serum oestradiol levels. In oncology
trials, this decline in oestradiol was associated with a 40% relative in-
crease in fracture rate compared to tamoxifen. When compared to
placebo, the excess fracture rate during AI therapy was considered to be
less, but the risk has actually been underestimated because the fractures
were only reported as adverse events in oncology trials [30]. The in-
creased risk is independent of the type of AI and, in the ABCSG-18
study, the only trial in which the fracture incidence was the primary
endpoint, the fracture rate was 9.6% after 3 years and 26% after 7 years
in the placebo group receiving AIs only [31].
Pharmacological intervention for patients at risk of bone loss in-
cludes vitamin D supplementation (1000–2000 IU daily) and calcium
supplementation (1000 mg daily) is recommended if the dietary intake
is inadequate. Antiresorptive therapy is recommended in patients with
a baseline T score of<−2.0 or two or more clinical risk factors for
fracture [29]. Data from randomized clinical trials (RCTs) in> 5000
patients show that bisphosphonates and denosumab administered at
doses and schedules that are most often similar to those used for
postmenopausal osteoporosis can prevent bone loss in women with
breast cancer and even lead to an increase in BMD [29,32]. In post-
menopausal women, the choice of bisphosphonate is broader than in
premenopausal women, with evidence that ibandronate (150 mg oral
monthly), clodronate (1600 mg oral daily), risedronate (35 mg oral
weekly), alendronate (70 mg oral weekly) and zoledronic acid (4 mg IV
6 monthly) all prevent the bone loss associated with the use of AIs [32].
Although these trials were not designed with a fracture-prevention
endpoint, data from the osteoporosis setting have demonstrated a good
correlation between BMD improvements and fracture prevention. The
ABCSG-18 trial, which randomized postmenopausal women on AIs to
denosumab 60 mg injection every 6 months or placebo, found that
active treatment reduced the risk of ﬁrst clinical fracture relative to
placebo by 50%. Five years following randomization, 15% of placebo
patients but slightly over 5% of denosumab-treated patients had ex-
perienced a fracture. A similar signiﬁcant protective eﬀect was seen
both in women with a baseline T-score<−1 and in those with a T
score≥−1. Since anti-resorptive treatments can cause osteonecrosis of
the jaw, the investigators established a proactive screening and mon-
itoring system within the trial. Despite this approach and expert ad-
judication of suspected episodes of dental problems, they did not
identify any cases of osteonecrosis of the jaw. Furthermore, atypical
fractures have been reported with anti-resorptive agents, but were not
seen in ABCSG-18.These new ﬁndings will have to be considered when
updating the guidelines for the prevention of AI-induced bone loss,
especially given that denosumab was not associated with additional
toxicity [31,33]. An increased risk of multiple vertebral fractures on
denosumab discontinuation has recently been described in case reports,
particularly in patients with prior vertebral fractures. Although no
guidelines are yet available in the setting of CTIBL, when denosumab is
stopped, we advise to start a replacement antiresorptive therapy to
sustain antifracture eﬃcacy.
Several other trials evaluating zoledronic acid primarily as a bone
protective agent during AI treatment for postmenopausal women with
breast cancer also investigated the eﬀects of bisphosphonate use on
disease outcome. The largest of these trials (ZO-FAST) reported fewer
recurrences in women receiving immediate bone protection with zole-
dronic acid compared with the control arm where the bisphosphonate
was only introduced months or years later if there were changes in BMD
or a fracture that warranted intervention [34]. The improvement in
disease outcomes in both zoledronic acid and oral clodronate trials
were predominantly and most consistently mediated by a reduction in
bone metastases as the ﬁrst distant metastatic site. To investigate the
available evidence in a more robust and precise fashion, the Early
Breast Cancer Trials Collaborative Group (EBCTCG) has conducted a
formal meta-analysis of individual patient data from 18,766 women in
26 randomized trials of adjuvant bisphosphonates for early breast
cancer [35]. The majority of these patients received either oral clo-
dronate 1600 mg daily or intravenous zoledronic acid 4 mg every 6
months. For the entire population, bisphosphonates reduced both the
number of patients with ﬁrst distant recurrence in bone (RR = 0.83;
95%CI 0.73–0.94, p = 0.004) and the incidence of breast cancer mor-
tality (RR = 0.91; 95%CI 0.83–0.99, p = 0.04). The eﬀect was larger
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when the analysis was restricted to postmenopausal women
(n = 11767). In these women, bisphosphonates improved not only re-
currence in bone (RR = 0.72; 95%CI 0.60–0.86, p = 0.002) but also
overall breast cancer recurrence (RR = 0.86; 95%CI 0.78–0.94,
p = 0.002) and, most importantly, markedly reduced breast cancer
mortality (RR = 0.82; 95%CI 0.73–0.93, p = 0.002). Bisphosphonates
did not appear to modify any disease outcomes in premenopausal
women [35]. From the data provided, the authors state they were un-
able to assess the incidence of osteonecrosis of the jaw, but previous
reports suggest it ranges from under 1% with clodronate, ibandronate,
or 6-monthly zoledronic to about 2% with more intensive zoledronic
acid schedules for 3–5 years of therapy. The risk-beneﬁt ratio is thus
largely favourable even if the selection of patients for such prevention
treatment remains, however, unclear. A European expert panel con-
cluded that the data supported the use of adjuvant bisphosphonates in
postmenopausal women, but experts were divided on restricting the
adjuvant use of these antiresorptive agents to women considered at
intermediate or high risk of recurrence rather than the unselected use
across all risk groups. The panel was in agreement that either daily oral
clodronate or intravenous zoledronic acid (every 6 months) are the
preferred agents and recommended treatment for 3–5 years [36]. The
results of trials testing the antitumor eﬃcacy of denosumab in the ad-
juvant setting are eagerly awaited and should be available soon.
4. Fracture rate in long-term breast cancer survivors
Studies of bone health status among survivors of breast cancer
published more than a decade ago have provided conﬂicting results but
tended towards an increased risk of fracture [37–40]. For example, the
Women’s Health Initiative showed that postmenopausal survivors of
breast cancer are at increased risk for clinical fractures [40] but the
Long-term Survivorship in Older Women with Early-stage Breast Cancer
(BOW II) study suggested that long-term survivors of early-stage breast
cancer diagnosed at age 65 or older are not at increased risk of osteo-
porotic fractures compared to age-matched women without breast
cancer [39]. However, these studies have some limitations such as not
taking into account the prevalence of fracture, stage of the disease or
treatment use. Moreover, these studies were designed before the use of
AIs for hormone responsive breast cancer, a treatment that negatively
aﬀects bone health, as reported in the previous section.
More recent studies have attempted to overcome these limitations.
In a population-based historical cohort study of 608 US women with
invasive breast cancer followed for 5776 person-years, the standardized
incidence ratio was 1.2 (95% conﬁdence interval [CI] 0.99–1.3) for
total fracture risk and 0.9 (95% CI 0.7–1.2) for osteoporotic fracture
risk alone [41]. In another study, 1286 women aged 65 and older who
were alive and recurrence-free 5 years after a diagnosis of early-stage
breast cancer and the same number of matched controls were followed
for 10 years [42]. At the end of the follow-up period, no diﬀerence was
observed in the fracture rates between groups (hazard ratio (HR) = 1.1,
95% conﬁdence interval (CI) = 0.9–1.3).
The site of fracture is also of interest. Indeed, trabecular bone sites
such as the spine are metabolically more active than cortical bone sites
and are likely to be a more sensitive indicator of abnormal bone me-
tabolism. An interesting study was designed to look at the special and
temporal fracture pattern in breast or gynaecological cancer [43]. De-
spite the limited number of subjects included (n = 139), the pattern of
skeletal fracture was similar between cancer survivors and the general
population. The most common fracture sites were the vertebrae (16%),
feet and toes (15%), ribs (12%), hands and ﬁngers (10%), and pelvis
(8%). The authors also showed that the median time from cancer di-
agnosis to fracture varied according to age (p < 0.01), from a high of
3.2 years for ages 50–59 to a low of 1.2 years for patients older than 70
[43].
The consequences of fractures have also been compared between
cancer survivors and control subjects. In a study performed in Sweden,
it was shown that compared with the general population, breast cancer
patients had incidence rate ratios of 1.25 (95% CI: 1.23–1.28) and 1.18
(95% CI: 1.14–1.22) for hospitalization due to any bone fracture and
hip fracture, respectively [44]. However, it should be noted that the co-
morbidities at baseline, assessed with the Charlson index, were asso-
ciated with the risk of being hospitalized with bone fracture.
At last, it should be noted that all these studies have been mainly
performed on Caucasian women and that the association in other ethnic
groups may yield diﬀerent results. For example, in a study performed
on 22,076 Taiwanese women with breast cancer, the incidence of all
types of fracture was higher in the breast cancer cohort than in the
88,304 women without cancer, with adjusted HRs of 1.18 (95% CI,
1.03–1.35) for hip fractures, 1.12 (95% CI, 0.98–1.28) for forearm
fractures and 1.24 (95% CI, 1.04–1.48) for vertebral fractures [45].
In summary, the relation between breast cancer survival and future
risk of fracture remains under debate, although the most recent studies
suggest that Caucasian survivors do not have a signiﬁcantly increased
risk of osteoporotic fracture. However, it should be noted that all these
observational studies must be interpreted with caution because poten-
tial limitations such as the potential confounding by treatment indica-
tion are likely to be present and are very diﬃcult to take into account.
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